Recursion Pharmaceuticals, Inc. - Class A Common Stock
Recursion Pharmaceuticals, Inc. - Class A Common Stock
Aktie · US75629V1044 · RXRX (XNAS)
Übersicht Finanzkennzahlen
5,57 USD
23,23 % 1,05 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 23:59

Aktuelle Kurse von Recursion Pharmaceuticals, Inc. - Class A Common Stock

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
RXRX
USD
06.06.2025 23:59
5,57 USD
4,56 USD
+22,14 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 32,62 % 33,25 % -15,48 % -30,38 % -34,55 % -69,06 %

Firmenprofil zu Recursion Pharmaceuticals, Inc. - Class A Common Stock Aktie

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Unternehmensdaten

Name Recursion Pharmaceuticals, Inc. - Class A Common Stock
Firma Recursion Pharmaceuticals, Inc.
Symbol RXRX
Website https://www.recursion.com
Heimatbörse XNAS NASDAQ
ISIN US75629V1044
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Christopher C. Gibson Ph.D.
Marktkapitalisierung 2 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,8 T
Adresse 41 South Rio Grande Street, 84101 Salt Lake City
IPO Datum 2021-04-16

Ticker Symbole

Name Symbol
NASDAQ RXRX

Weitere Aktien

Investoren die Recursion Pharmaceuticals, Inc. - Class A Common Stock die halten, haben auch folgende Aktien im Depot:
Cyxtera Technologies, Inc.
Cyxtera Technologies, Inc. Aktie
LANGTON SECURITIES (2010-1) PLC FLTG RTE CLS Z1 NTS 18/12/54 £
LANGTON SECURITIES (2010-1) PLC FLTG RTE CLS Z1 NTS 18/12/54 £ Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025